Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18557487 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Non-Final OA | Merck Sharp & Dohme LLC |
| 17784718 | INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | Non-Final OA | Merck Sharp & Dohme LLC |
| 18550642 | METHOD OF DECREASING THE POPULATION OF FUSOBACTERIA IN THE GUT MICROBIOME | Non-Final OA | DSM IP Assets B.V. |
| 18255212 | STABLE ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-INDOL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID | Non-Final OA | LG CHEM, LTD. |
| 17768529 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | Final Rejection | The Board of Regents of The University of Texas System |
| 18037732 | THERAPIES FOR CANCER USING SMALL MOLECULES THAT BIND TO AND INHIBIT RAL INTERACTING PROTEINS | Final Rejection | Texas Tech University System |
| 18266525 | SMALL MOLECULES AND THEIR USE AS MALT1 INHIBITORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18035313 | SULFUROUS COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | Non-Final OA | Merck Patent GmbH |
| 17917438 | USE OF MASITINIB FOR THE TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) | Final Rejection | THE UNIVERSITY OF CHICAGO |
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Final Rejection | ARES TRADING S.A. |
| 18542376 | COMPOUNDS THAT SYNERGIZE WITH COPPER TO KILL STREPTOCOCCUS PNEUMONIAE | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17600817 | METHODS AND COMPOSITIONS FOR TREATING TUMORS USING TRANSCRIPTION INHIBITION AND DNA DAMAGE | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 18009072 | THE PROCESS OF PREPARATION OF ANTHRANILAMIDES | Final Rejection | Adama Makhteshim Ltd. |
| 18542628 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Non-Final OA | BioTheryX, Inc. |
| 18542101 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Non-Final OA | TRAWS PHARMA, INC. |
| 18565530 | NOVEL SQUARAMIDE DERIVATIVE AND USE THEREOF | Non-Final OA | KOSIN UNIVERSITY INDUSTRY-ACADEMY COOPERATION |
| 18562917 | COMPOSITION FOR TOPICAL TREATMENT OF MICROBIAL INFECTIONS | Non-Final OA | HENNEPIN LIFE SCIENCES, LLC |
| 18253229 | Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors | Final Rejection | Taiho Pharmaceutical Co., Ltd. |
| 18486463 | PROCESS FOR PRODUCING HEXAMETHYLENEDIAMINE FROM CAPROLACTAM | Non-Final OA | Ascend Performance Materials Operations LLC |
| 18485010 | SPIROCYCLIC IMIDAZOLIDINONES AND IMIDAZOLIDINEDIONES FOR TREATMENT OF LIGHT CHAIN AMYLOIDOSIS | Non-Final OA | Protego Biopharma, Inc. |
| 18248119 | USE OF AN ERK INHIBITOR FOR THE TREATMENT OF MYELOFIBROSIS | Non-Final OA | University of Basel |
| 18263936 | PIM KINASE INHIBITOR | Final Rejection | Hangzhou Biosun Pharmaceutical Co., Ltd. |
| 18268818 | SALT FORM OF TETRA-SUBSTITUTED OLEFIN COMPOUND, CRYSTAL, AND PREPARATION METHOD THEREFOR | Final Rejection | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. |
| 18261899 | FGFR KINASE INHIBITOR AND USE THEREOF | Non-Final OA | YA THERAPEUTICS INC |
| 18266294 | Novel Bifunctional Molecules For Targeted Protein Degradation | Non-Final OA | Amphista Therapeutics Limited |
| 17641665 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH CLEC16A DYSFUNCTION OR LOSS | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17908670 | FOLATE COMPOSITIONS | Final Rejection | APROFOL AG |
| 17604801 | COMPOSITIONS AND METHODS FOR POTENTIATING DERIVATIVES OF 4-AMINOPHENOLS | Final Rejection | SCISPARC LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy